SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 25, 2025

Prashant Patel
Chairman and Chief Executive Officer
Crown Reserve Acquisition Corp. I
Conyers Trust Company (Cayman) Limited
Cricket Square, Hutchins Drive
PO Box 2681
Grand Cayman KY1-1111
Cayman Islands

 Re: Crown Reserve Acquisition Corp. I
 Registration Statement on Form S-1
 Filed May 30, 2025
 File No. 333-287674
Dear Prashant Patel:

 We have reviewed your registration statement and have the following
comments.

 Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Cover Page

1. Please disclose whether there are any limitations to your redemptions.
Refer to Item
 1602(a)(2) of Regulation S-K.
2. Where you disclose the amount of compensation received or to be received
by the
 sponsor, its affiliates, and promoters, please also discuss whether the
compensation
 and securities issuances could result in material dilution of the
purchasers' equity
 interests. Refer to Item 1602(a)(3) of Regulation S-K.
 June 25, 2025
Page 2
3. You state that each unit includes one right to receive one-seventh of
one Class A
 ordinary share. Please expand your disclosure to explain whether
fractional shares will
 be issued in connection with the rights. See Item 501(b)(2) of
Regulation S-K.
4. Please also disclose the aggregate amount of public units that the
non-managing
 sponsor investors have expressed an interest to purchase. In this
regard, we note your
 statement that none of them have expressed an interest in purchasing
more than 9.9%
 of the units to be sold in this offering.
Summary, page 1

5. Revise your disclosure to address plans to seek additional financing and
how such
 financing may impact unaffiliated shareholders. Refer to Item 1602(b)(5)
of
 Regulation S-K.
6. Please address whether there are any limitations on the number of
extensions you may
 seek to extend the deadline for your initial business combination. Refer
to Item
 1602(b)(4) of Regulation S-K.
7. You define "Permitted Withdrawal" to include withdrawals of interest
earned on the
 trust account to fund your working capital requirements, and you have
disclosure,
 such as on page 43, that interest released at liquidation will be net of
such Permitted
 Withdrawals. However, you also state elsewhere, including on the cover
page, that
 interest will only be released from the trust account to pay your tax
obligations. Please
 revise your disclosures throughout for consistency.
8. In your discussion of the prior SPAC experience of your officers and
director
 nominees, please revise to balance your disclosure by clarifying whether
an entity was
 able to complete the business combination within the original completion
window or
 whether there were extensions of time to complete the transaction or if
they have not
 yet completed a combination, whether there have been extensions. Also
discuss the
 amount of shareholder redemptions in connection with such transactions.
Please also
 revise to remove outdated listing information with respect to references
to exchanges
 and ticker symbols.
Sponsor Information, page 7

9. Please revise your tabular disclosures starting on pages 9 and 99 to
disclose the
 natural persons and entities subject to the transfer restrictions. We
also note your
 statement on pages 11 and 100 that CCM may release certain securities
subject to the
 lock-up. Please revise to clarify CCM's role in these transactions.
Refer to Item
 1603(a)(9) of Regulation S-K.
10. Please reconcile your disclosure on page 33 of your registration
statement that there
 will not be any finder's fees paid to your sponsor, officers, directors,
or their affiliates
 in connection with services rendered prior to or in connection with an
initial business
 combination with your disclosure on pages 8 and 97 that there is an
undetermined
 amount expected to be paid to your sponsor for consulting, success, or
finder fees in
 connection with the consummation of an initial business combination.
11. We note your disclosure that if you increase or decrease the size of
your offering, you
 will effect a capitalization or share surrender or redemption or other
appropriate
 mechanism to maintain the ownership of the founder shares by the initial
shareholders
 June 25, 2025
Page 3

 at 20% of the issued and outstanding ordinary shares. Please revise to
disclose, here
 and elsewhere as applicable, this initial issuance as compensation and
the extent to
 which it may result in material dilution to your shareholders. Refer to
Item 1602(b)(6)
 of Regulation S-K.
Proposed Business
Permitted Purchases of Our Securities, page 27

12. We note disclosure regarding your letter agreement with your sponsor,
officers, and
 directors to vote any founder shares and public shares in favor of your
initial business
 combination. In addition, we note disclosures, such as on pages 43 and
104, that your
 sponsor, directors, or officers may purchase shares in privately
negotiated transactions
 for the purpose of voting such shares in favor of the business
combination. We also
 note your statement on page 25 that there is no limit on the price that
they may pay.
 Please tell us how such purchases would comply with Exchange Act Rule
14e-5.
 Refer to Tender Offer Rules and Schedules C&DI 166.01 for guidance.
Risk Factors, page 40

13. Please include a risk factor that describes the potential material
effect on
 your shareholders of the stock buyback excise tax enacted as part of the
Inflation
 Reduction Act in August 2022. If applicable, include in your disclosure
that the excise
 tax could reduce the trust account funds available to pay redemptions or
that are
 available to the combined company following a de-SPAC transaction. Also
describe,
 if applicable, the risk that if existing SPAC investors elect to redeem
their shares such
 that their redemptions would subject the SPAC to the stock buyback
excise tax, the
 remaining shareholders that did not elect to redeem may economically
bear the impact
 of the excise tax.
14. We note that transfers may be made in connection with any forward
purchase
 agreement or similar arrangements. Please add risk factor disclosure
about risks that
 may arise from the sponsor or a sponsor affiliate having the ability to
remove itself as
 your sponsor before identifying a business combination, including
through the
 unconditional ability to transfer the founder shares or all or any
portion of its
 membership interests in the sponsor. Address the consequences of such
removal to the
 company's ability to consummate an initial business combination,
including that any
 replacement sponsor could have difficulty finding a target.
If we seek shareholder approval. . ., page 44

15. Please expand this risk factor to discuss the amount of public shares
that would be
 needed to vote in favor of the initial business combination if only a
minimum number
 of shares representing a quorum are voted and to explain how many votes
will be
 needed if all the non-managing sponsor investors vote in favor of the
transaction. Also
 revise the first bullet on page 18 and add a bullet on page 37 to
include corresponding
 disclosures.
 June 25, 2025
Page 4
Risks Relating to Our Search for, and Consummation of or Inability to
Consummate, a
Business Combination
If we are deemed to be an investment company under the Investment Company Act,
we may
be required to institute burdensome compliance . . ., page 44

16. Where you disclose the risk that you may be considered to be operating
as an
 unregistered investment company, please expand your disclosure to
disclose the risk
 that despite your investment of the proceeds in certain specified
assets, you could
 nevertheless be considered to be operating as an unregistered investment
company. In
 addition, please confirm that if your facts and circumstances change
over time, you
 will update your disclosure to reflect those changes impact the risk
that you may be
 considered to be operating as an unregistered investment company.
Use of Proceeds, page 75

17. Please revise and ensure the mathematical accuracy of the percentage to
be held in
 Trust account, as $149.92 million to be held in the Trust account is
less than 100% of
 the public offering size totaling $150 million. We also note your
statement on page 55
 that $152,610,000 will be held in the trust account, and your statement
on the cover
 page that $150,000,000 will be deposited into a trust account. Please
revise your
 disclosures regarding the amount to be held in the trust account for
consistency.
Dilution, page 80

18. Please expand your disclosure, outside the table, to describe each
material potential
 source of future dilution following your registered offering, including
sources not
 included in the table with respect to the determination of net tangible
book value per
 share, as adjusted. Your revisions should address, but not be limited
to, founder
 shares' anti-dilution rights, shares that may be issued in connection
with the closing of
 your initial business combination, and up to $5,000,000 of working
capital loans that
 may be converted into private placement units. Refer to Item 1602(c) of
Regulation S-
 K.
19. We note the disclosure in your filing that your amended and restated
memorandum
 and articles of association will provide that you may not redeem your
public shares in
 an amount that would cause your net tangible assets, after payment of
the
 underwriters' fees and commissions, to be less than $5,000,001. Please
tell us how you
 considered this redemption restriction in your determination of your
maximum
 redemption threshold for your dilution presentation. Given your
redemption
 limitation, amend your disclosure to present the number of ordinary
shares redeemed
 and amounts paid for such redemptions as quartile percentages of the
maximum
 redemption rather than based on the entire amount of shares to be sold
to public
 shareholders. Refer to Item 1602(c) of Regulation S-K.
Management, page 121

20. Please revise your disclosure to ensure you have disclosed the business
experience,
 principal occupations, and employment of each director and executive
officer
 named during each of the past five years, including dates and duration
of employment.
 Refer to Item 401(e) of Regulation S-K. Also revise the table on page
121 to clarify
 June 25, 2025
Page 5

 the individuals who are currently director nominees, or advise, and
include the class
 of each director and director nominee. In this regard, we note the
consents filed as
 Exhibits 99.3-99.6 and your statement on page 123 and elsewhere that
your board is
 divided into three classes.
21. Please ensure that your table disclosing the contractual obligations and
fiduciary
 duties of your officers and directors is complete. In this regard, we
note that it appears
 Prashant Patel may be serving as Vice Chairman of the Board of
Wellgistics Health,
 Inc. and that Eric Sherb is serving as Chief Financial Officer of SME
Entertainment,
 Inc.
Principal Shareholders, page 131

22. We note your disclosure that Eric Sherb has voting and investment
discretion with
 respect to the founder shares held by the sponsor. Please address all
persons with
 direct and indirect material interests in the sponsor, including the
nature and amount
 of their interests. Refer to Item 1603(a)(7) of Regulation S-K.
Financial Statements
Notes to Financial Statements
Note 9 - Subsequent Events, page F-18

23. We note you evaluated subsequent events through May 27, 2025, the date
that the
 financial statements were available for issuance. Please tell us what
consideration you
 gave to evaluating subsequent events through the audit report date
noted, and advise
 or revise accordingly. Refer to ASC 855-10-25.
Exhibits

24. We note your references to a letter agreement between you, your sponsor,
and your
 management. However, this agreement does not appear to be filed or
listed in the
 exhibit index. Please file this letter agreement. Refer to Item
601(b)(10) of Regulation
 S-K.
General

25. Please ensure that you define all acronyms or defined terms upon first
use. For
 example, you reference SAP units in the fourth paragraph of your cover
page but you
 do not define SAP until the tenth paragraph or SAP Unit until the
fourteenth
 paragraph.
26. Please discuss the general character of your sponsor's business and
describe the
 material roles and responsibilities of your sponsor, its affiliates, and
promoters in
 directing and managing your activities. Refer to Items 1603(a)(2) and
(a)(4) of
 Regulation S-K.
27. Please describe the experience of your sponsor, affiliates, and
promoters in organizing
 special purpose acquisition companies. Refer to Item 1603(a)(3) of
Regulation S-K.
28. With a view toward disclosure, please tell us whether your sponsor is,
is controlled
 by, or has substantial ties with a non-U.S. person. If so, also include
risk factor
 disclosure that addresses how this fact could impact your ability to
complete your
 initial business combination. For instance, discuss the risk to
investors that you may
 June 25, 2025
Page 6

 not be able to complete an initial business combination with a U.S.
target company
 should the transaction be subject to review by a U.S. government entity,
such as the
 Committee on Foreign Investment in the United States (CFIUS), or
ultimately
 prohibited. Disclose that as a result, the pool of potential targets
with which you could
 complete an initial business combination may be limited. Further,
disclose that the
 time necessary for government review of the transaction or a decision to
prohibit the
 transaction could prevent you from completing an initial business
combination and
 require you to liquidate. Disclose the consequences of liquidation to
investors, such as
 the loss of the investment opportunity in a target company, any price
appreciation in
 the combined company, and the warrants, which would expire worthless.
Underwriting, page 166

29. Please revise your underwriter's compensation table to include the SAP
units. In that
 regard, we note your disclosure on page 168 and elsewhere that these
items have been
 deemed compensation by FINRA. Please refer to Item 508(e) of Regulation
S-K.
 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

 Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

 Please contact Peter McPhun at 202-551-3581 or Mark Rakip at
202-551-3573 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Isabel Rivera at 202-551-3518 or Dorrie Yale at 202-551-8776 with any
other
questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Real
Estate & Construction
cc: Rajiv Khanna, Esq.
</TEXT>
</DOCUMENT>